As of May 23
| +0.08 / +1.17%|
The 7 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 13.00, with a high estimate of 17.00 and a low estimate of 9.00. The median estimate represents a +87.86% increase from the last price of 6.92.
The current consensus among 7 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.